The study aim was development of composite bone cements with lower monomer content, viscosity and modulus but a higher conversion and strength than the commercial composite Cortoss TM .
Introduction

Osteoporotic fracture
Approximately 50-60 % of all postmenopausal women in the United States and Europe suffer an osteoporotic fracture of some kind (1) (2) (3) . Vertebral fractures are one of the most common (4, 5) . One method of treatment is Vertebroplasty. In this procedure bone cement is injected into the damaged vertebrae to relieve pain and improve function (6) . Currently there are two main types of polymeric bone cement recommended for this procedure (7) . Their properties and current limitations are discussed below.
PMMA cements (Polymethylmethacrylates)
Commercial PMMA bone cements largely consist of PMMA beads dispersed in methyl methacrylate (MMA) monomer (8) . MMA, being a small methacrylate has low biocompatibility and therefore may result in a hypersensitivity reaction (9) . PMMA cements are also unstable and non-sterile after mixing in the operating theatre by surgeons. Other PMMA problems include its high temperature rise (76 -110°C) and shrinkage during polymerization (10, 11) . The heat may result in tissue necrosis (10) whilst polymerization shrinkage may cause loosening of the bone cement (12) . In addition, PMMA cements can be of insufficient strength in high load bearing applications (7) . It may also be stiffer than the surrounding bone (13) and thereby discourage bone regrowth (14) . Furthermore, particulate debris generated upon wear may cause an inflammatory response (10).
Composite bone cements
Composite bone cements overcome many of the above disadvantages of conventional PMMA cements (15) . One commercial example used mainly for vertebroplasty is Cortoss. This consists of long chain monomers, including bisphenol a glycidyl methacrylate (Bis-GMA) and ethoxylated bisphenol a glycidyl dimethacrylate (Bis-EMA) with tri-ethylene glycol dimethacrylate (TEGDMA) diluent (16) . It also contains glass fillers, and an initiator/activator system similar to PMMA. It is supplied as pre-mixed activator/initiator pastes in a double barrel syringe making handling easier. High monomer molecular weight increases biocompatibility and decreases the polymerization exotherm and shrinkage (7, (17) (18) (19) . Furthermore, use of dimethacrylates instead of mono-methyl methacrylate enables crosslinking which is known to increase wear resistance (20) .
Even with the use of high molecular weight monomers, Cortoss can still generate high temperatures (63 °C) and shrinkage during cure (7) . This is due to the high monomer volume fraction (32 wt% which equates to 43 vol%). Additionally, the viscosity of Cortoss is high which means wide bore syringe tips must be used. A third problem with Cortoss can be BisGMA estrogenmimicking activity (22) . Furthermore, the high rigidity of this monomer also restricts conversion (64 %) (21) . Low conversion limits crosslinking (20) and may increase monomer leakage from the set cement in an aqueous environment. Finally, Cortoss strength is insufficient for some applications (7) .
UDMA is an alternative high molecular weight dimethacrylate that is currently used in some light cure dental composites. It has lower viscosity, greater chain flexibility and higher conversion than Bis-GMA (17, 20) . Furthermore, it has lower water sorption / solubility and therefore better resistance to aqueous environments (23).
Aims
The aim of this study was therefore to develop chemically curable composite bone cements similar to Cortoss using UDMA instead of Bis-GMA.
In comparison with Cortoss, the new formulations should preferably have:
 Lower monomer content (< 30 wt%) to ensure low heat and shrinkage during curing.  Lower viscosity for use in finer bore syringes.  Comparable manipulation time after mixing.  High monomer conversion for low toxicity and greater crosslinking.  Higher strength and low stiffness.
Objectives
The first objective was production of cements of increasing powder content and therefore viscosity. Maximum feasible powder content was to be assessed via cement ability to flow readily through a small bore syringe tip. The second objective was to manipulate curing time by changing the initiator and activator levels. The final monomer conversion, strength and modulus of formulations were then compared with those of Cortoss.
Materials and Methods
Materials
Cement components are given in Table 1 
Setting kinetics and conversion
To quantify setting kinetics, formulations (n=3) were applied to the diamond of an ATR FTIR spectrometer directly from the mixing tip of the syringe and covered with acetate sheet. Spectra were recorded with a resolution of 8 cm -1 for 40 minutes at 26 and 37 ºC (see Figure 1 ). Methacrylate monomers have strong absorbance at 1319 cm -1 (C-O stretch) which shifts to 1244 cm -1 upon polymerization. The fraction of monomer polymerised (M) was therefore calculated using the height of this peak above background at 1320 cm -1 with equation 1 (20, 24) .
Equation 1 Reaction extent
Where A o and A t are initial absorbance and absorbance at time "t" at 1319 cm 
Biaxial flexural strength (BFS) and modulus
For biaxial flexural strength and modulus determination, discs (n=6) of 10 mm diameter and 1 mm thickness were prepared. 24 hours after mixing, specimens were placed for a further 24 hours in water or simulated body fluid (SBF) at 37°C. BFS was performed using an Instron 4502, mechanical tester with a "ball on ring jig". Crosshead speed was set as 1mm/min. Biaxial flexural strength (BFS (25, 26) ), σ, and modulus E were calculated using Equations 2 and 3 respectively (27) .
Equation 2 Biaxial flexural strength [ ] [ ]
Equation 3 Biaxial flexural modulus.
Where, P is maximum load, a is support radius, t is average specimen thickness, µ is Poisson ratio (0.3) (28), ∆P/∆W is the maximum gradient of force versus displacement and β is the central displacement function equal to 0.502 (27) . 95% CI error bars are provided in all Figures.
Results
Handling
Formulations with low powder content were much less viscous than those with high powder content. Even with the highest powder content (80 wt%), the formulations could be mixed using a syringe with a finer bore mixing tip than required for Cortoss ( Figure 2 ). 
Inhibition time and half life
Increasing the powder content from 70 to 80 wt% had only minor effects on inhibition times and half-life ( Figure 4 ). These times were comparable with those of Cortoss (130 and 232 s). 
Final conversion
Lower powder content reduced slightly the final conversion ( Figure 6 ). Final conversion fraction with Cortoss was 0.64. 
Modulus
Powder content and storage solution type had no signficiant effect on modulus ( Figure 10 ). The average modulus of 3.3 GPa compares with 3.4 GPa for Cortoss. 
Discussion and onclusion C
Chemical cured composite based bone cements are basically composed of a resin matrix, inorganic fillers, and a coupling agent. The, size, type, and distribution of monomer, filler content, as well as coupling between particles and matrix all influence setting behaviour, conversion of the monomer and mechanical behaviour.
Use of UDMA instead of BisGMA in a composite bone cement enabled production of a low viscosity formulation that could be used in a double barrel syringe with fine mixing tip. Finer tip would allow more minimally invasive proceedures. Low viscosity was possible with high powder content and 1/3 rd less monomer than in
Cortoss. Both polymerisation heat and shrinkage will therefore also be expected to be reduced by a similar fraction. Less heat generation should correspond with reduced thermal shock and tissue necrosis (29) .
Various techniques have been used for assessment of cement reaction rate and final conversion. Fourier transform infrared (FTIR) and Raman spectroscopies have been commonly applied for direct quantification of reaction rate and monomer conversion (30). In the above studies, both cure rate and final conversion varied little with experimental composite powder content but increased with raising temperature. The more rapid cure at body temperature is beneficial to prevent monomer leakage from the site of application. Experimental composite cure rate can be readily varied for different procedures by changing initiator / activator concentrations. Doubling DMPT raised cure rate and conversion more than BP. The final conversion for the experimental materials was higher than Cortoss which means less monomer content and more crosslinking which should improve biocompatibility and wear resistance respectively.
The composite based materials should have sufficient mechanical properties to withstand the stresses created during movement. It has been suggested that the biaxial flexural test used in the above study provides a more reliable testing method for resin-based composites than three-point flexure (25, 26) . Most of the composite based cements have high compressive strength (CS) but have low BFS(7). Strength was not significantly affected by storage solution or powder content. It was raised, more by increasing the initiator rather than the activator concentration. All experimental composites had higher strength than Cortoss. The modulus of the experimental composites was comparable with that of Cortoss except for formulations with low BP in which case experimental modulus was reduced.
